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Background: The use of mother’s own breast milk during initial hospitalization has a positive impact not only in
reducing potential serious neonatal morbidities but also contribute to improvements in neurodevelopmental
outcomes. Mothers of very preterm infants struggle to maintain a supply of breast milk during their infants’
prolonged hospitalization. Galactogogues are medications that induce lactation by exerting its effects through
oxytocin or prolactin enhancement. Domperidone is a potent dopamine D2 receptor antagonist which stimulates
the release of prolactin. Small trials have established its ability in enhancing breast milk production. EMPOWER was
designed to determine the safety and efficacy of domperidone in mothers experiencing an inadequate milk supply.
Methods/design: EMPOWER is a multicenter, double masked, randomized controlled phase-II trial to evaluate the
safety and effectiveness of domperidone in those mothers identified as having difficulty in breast milk production.
Eligible mothers will be randomized to one of two allocated groups: Group A: domperidone 10 mg orally three
times daily for 28 days; and Group B: identical placebo 10 mg orally three times daily for 14 days followed by
domperidone 10 mg orally three times daily for 14 days. The primary outcome will be determined at the
completion of the first 2-week period; the second 2-week period will facilitate answering the secondary questions
regarding timing and duration of treatment. To detect an estimated 30% change between the two groups (from
40% to 28%, corresponding to an odds ratio of 0.6), a total sample size of 488 mothers would be required at 80%
power and alpha = 0.05. To account for a 15% dropout, this number is increased to 560 (280 per group). The
duration of the trial is expected to be 36–40 months.
Discussion: The use of a galactogogue often becomes the measure of choice for mothers in the presence of
insufficient breast milk production, particularly when the other techniques are unsuccessful. EMPOWER is designed
to provide valuable information in guiding the practices for this high-risk group of infants and mothers. The results
of this trial will also inform both mothers and clinicians about the choices available to increase and maintain
sufficient breast milk.
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Despite the recent perinatal and neonatal technological
advances, at least 8.2% of births in Canada are preterm
(<37 weeks gestation), a figure that has continued to
rise [1,2]. The very preterm infant is often growth
restricted because of the concurrent illnesses and diffi-
culties in optimizing energy and nutrient intake for nor-
mal growth [3]. Studies have suggested that early
nutritional intervention (breast milk and preterm for-
mula) that will support growth, in particular brain
growth, will lead to an improved outcome even in the
presence of injury [4-6]. There is further evidence to
suggest that the use of mother’s own breast milk com-
pared to infant formula during initial hospitalization has
a positive impact not only in reducing potential serious
neonatal morbidities but also contribute to improve-
ments in neurodevelopmental outcomes [6-12]. There is
a growing movement in neonatal care for very preterm
infants to receive breast milk as the primary source of
nutrition rather than rely on preterm formula. Mothers
are therefore encouraged to begin pumping their breasts
to provide breast milk for their infants. With preterm
infants requiring hospitalization for anywhere from 10–
16 weeks before their discharge from initial
hospitalization, continued and sustained breast milk vol-
ume can prove to be a challenge to even the most dedi-
cated of mothers. Most mothers of very preterm
infants, for a variety of reasons such as illness, stress
and other factors related to preterm birth, are unable to
express sufficient amounts of milk to exclusively feed
their infants [11-15].
There have been many identified and studied non-
pharmacological measures such as emotional support,
kangaroo care, skin-to-skin contact, expressing breast
milk at the infant’s bedside, increasing pumping fre-
quency and duration and types of mechanical expres-
sion that have been found to contribute to variable
levels of success in augmenting the breast milk produc-
tion in mothers of preterm infants [16]. For those
mothers in whom milk production has declined and is
not responding to non-pharmacologic measures, the
use of galactogogues is often considered. GalactogoguesTable 1 Outlines the series of small trials that have evaluated
infants
Study Domperidone N Placebo Rand
De Leo [18] 15 Y N
Petraglia [19] 17 Y N
da Silva [20] 20 Y Y
Campbell-Yeo [21] 46 Y Y
Ingram [22] 80 Metoclopromide Y
Knoppert [23] 15 N Yare medications that induce lactation generally from
exerting its effects through oxytocin or prolactin en-
hancement [17]. The primary galactogogues used today
for prolactin enhancement are dopamine antagonists
with the most widely studied being metoclopramide
and domperidone. Domperidone is a potent dopamine
D2 receptor antagonist and was developed and mar-
keted as a prokinetic and antiemetic agent. By blocking
dopamine D2 receptors in the anterior pituitary, dom-
peridone stimulates the release of prolactin Table 1
[18-23].Rationale for phase II trial
Mothers of preterm infants are at a higher risk of a de-
cline in milk production. It has been recommended that
they should be evaluated no later than two weeks post-
partum to determine what intervention may be required
to assist them in augmenting and maintaining an ad-
equate supply of milk [24]. Although other measures can
and should be considered, the use of a galactogogue
often becomes the measure of choice, particularly when
the other techniques are unsuccessful. The limited body
of research on domperidone suggests that it has poten-
tial as a galactogogue in mothers of preterm infants; this
has led to widespread use of this medication. However,
there is a paucity of research to best guide clinicians as
to the optimal dose, timing of administration and dur-
ation of treatment and to reaffirm safety. EMPOWER
was initiated to firmly establish the safety of domperi-
done for mothers of preterm infants but also guide clini-
cians regarding initiation, timing and duration of
treatment.Methods/design
Primary research question
The primary research question is: in mothers of preterm
infants 23–29 completed weeks (23 1/7-29 6/7 weeks)
gestation at birth who are pumping to provide
expressed breast milk for their infant(s) and are identi-
fied as having an inadequate milk supply, does the ad-
ministration of domperidone compare to placebothe efficacy of domperidone in mothers of preterm
omization Intervention Findings
10 mg TID 4d " lactation
10 mg TID 10d " PRL, BM
10 mg TID 7d " PRL, BM
10 mg TID 14d "" PRL, BM
10 mg TID 10d " BM
10 mg vs. 20 mg TID 4 weeks " BM
Asztalos et al. BMC Pregnancy and Childbirth 2012, 12:87 Page 3 of 6
http://www.biomedcentral.com/1471-2393/12/87increase breast milk volume without any signs of harm
over a 2 week period?Figure 1 EMPOWER Schema.Secondary research questions
There are several secondary research questions:
i. Is there a relationship between the volume of breast
milk produced and timing of initiation and duration
of domperidone to treat mothers with defined low
breast milk supply?
ii. Does gestation at birth contribute to any treatment
effect from domperidone in mothers with defined
low breast milk supply?
iii. Is there a difference in the volume of breast milk
produced in mothers identified having an inadequate
supply within 7–14 days post delivery versus
mothers identified 15–21 days post delivery?
iv. Is there a difference in the use of supplementation
such as donor breast milk or preterm infant formula
between the different strategies of administration
during the study period?
v. Is there a difference in the use of supplementation,
such as formula or donor breast milk by the mother
to her infant at 40 weeks post conceptual age (term)
and at 6 weeks corrected age (6 weeks post term)
between the two groups?
vi. Is there a difference in potential adverse events or
effects, in particular, those related to gastrointestinal
or cardiac difficulties between the two approaches?Design
EMPOWER is a multi-centre, double-masked, rando-
mized controlled trial in which 560 mothers will rando-
mized to one of two allocated groups: Group A:
domperidone 10 mg orally three times daily for 28 days;
and Group B: identical placebo 10 mg orally three times
daily for 14 days followed by domperidone 10 mg orally
three times daily for 14 days. (Figure 1) The primary
outcome will be determined at the completion of the
first 2-week period comparing study drug and placebo;
the second 2-week period will facilitate answering the
secondary questions regarding timing and duration of
treatment. The mothers will be contacted when their
infants are term gestation (40 weeks post conceptual
age) and 6 weeks corrected (6 weeks post date of con-
finement) to document the feeding patterns (breastfeed-
ing/bottle feeding), continued frequency of breast
stimulation, additional use of a galactogogue or alterna-
tive after the study period, and the use of supplementa-
tion other than mother’s own milk for their infants at
these time points. In addition, the mothers will be asked
to a few questions regarding the intervention and their
participation in the trial.Randomization
Upon consent, the site co-ordinator will be able to
randomize the mother using a 24 hour/day web-based
randomization service at the data coordinating centre
(DCC) at the Centre for Mother, Infant, and Child Re-
search (CMICR) in Toronto. A treatment number will
be issued which will correspond to the study medica-
tion at the centre which has been previously sent to
the site. The study allocation will be randomly
assigned in a 1:1 ratio in blocks of 4 and 8. The study
participants will be stratified by centre, gestational age
groupings (23–26 and 27–29 weeks gestation at deliv-
ery) and days post delivery (7–14 and 15–21 days post
delivery).Study setting
The study setting is multi-national with approximately
20–25 centres in Canada, Israel, Qatar, and Chile. En-
rollment began in June 2012 and is expected to be com-
pleted in 36–42 months.Ethics, informed consent and safety
Documented approval has been obtained from the Re-
search Ethics Boards/Institutional Review Boards of the
participating centres prior to study start. In addition
documented approval has been obtained from Health
Canada to study domperidone for this off-label indica-
tion. The study is also designed to conform to the Inter-
national Conference on Harmonization of good clinical
practice (GCP) guidelines [25], as well as local regula-
tions and policies as well as with the Declaration of Hel-
sinki. Written informed consent must be obtained from
each participant.
There is no interim analysis planned but regular safety
reviews are scheduled for every 100 patients recruited at
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reviewed by the Data Safety Monitoring Board (DSMB).
The DSMB will also have the right to review any vari-
ables that may have an impact on the trial.
Eligibility
Inclusion criteria The goal is to identify those mothers
truly at higher risk of not being able to produce and
maintain a supply of breast milk in sufficient quantities
for her infant.
i. mothers of a preterm infant born ≤ 29 completed
weeks gestation (23 1/7-29 6/7 weeks)
ii. postpartum period of 7–21 days
iii. mechanically pumping an minimum average of 6
times a day in the 4–7 days prior to entry
iv. experiencing inadequate milk supply defined as
providing <100% of the average of the daily
nutritional intake during the previous 72 hour
period prior to entry based on a fluid intake of
150 ml/kg/d or experiencing a clinical reduction of
30% from a peak volume during the previous
72 hour period prior to entry (maternal report). The
30% reduction reported by the mother will be
confirmed by lactation support personnel in the
NICU. In the case of mothers with twins, the
estimated fluid volume to be produced will be based
on the weight of the larger twin. Mothers can be
identified in the NICU as early as day 4 until day 18
post delivery.
Exclusion criteria
i. history of known or suspected cardiac
dysrhythmias (tachyarrhythmia, Q-Tc
prolongation) or currently on an anti-arrhythmic
medication
ii. currently experiencing mastitis
iii. previous breast surgery, including augmentation or
reduction, nipple piercing
iv. known chronic or debilitating illness, known
abnormal liver function, gastric abnormalities
(gastrointestinal hemorrhage, blockage or currently
treated acid reflux), HIV
v. known to a have prolactin-releasing pituitary tumor
vi. receiving medications known to alter the
metabolism and pharmacokinetics of domperidone
(eg. oral “azole” antifungals, erythromycin
antibiotics, MAO inhibitors) or medications that
have dopaminergic or antidopaminergic activity or
affect prolactin levels
vii. mother of higher order pregnancies (triplet, or
more)viii. current cigarette smoking (cigarette smoking is
known to diminish prolactin levels)
Duration of study period
The total study period for the study medication is
4 weeks (28 days). The study medication will end prior
to 28 days if any one of the following occurs:
i. if the infant dies during the study period
ii. mother’s refusal for ongoing participation with the
protocol
iii. if the mother is experiencing any irregular
heartbeats (documented by an ECG)
iv. if the Q-Tc interval in the ECG is > 0.44 sec (based
on standard ECG run at 25 mm/sec) for the mother
v. if the infant is demonstrating an irregular heartbeat
or prolonged Q-Tc interval confirmed by ECG;
blood for domperidone level will be drawn on the
infant only if this occurs.
Study outcomes
Primary outcome
The primary outcome is the difference between the two
groups in achieving a 50% increase in breast milk vol-
ume at the end of the first 2-week period (mean day 14
volume- mean day 0 volume at entry).
Secondary outcomes
The secondary outcomes include:
i. mean difference in the tabulated volume in breast
milk recorded between the two groups at 2 and
4 weeks (mean day 14 or 28 volume- mean day 0
volume at entry)
ii. mean within-subject differences between the two
groups at 2 and 4 weeks (mean day 14 or 28
volume- mean day 0 volume at entry)
iii. effect of gestational age at the time of delivery on
the volume of milk (23–26 and 27–29 weeks
gestation at delivery) between the two groups
iv. effect of timing of inadequate milk supply post
delivery on the volume of milk (7–14 and 15–
21 days) between the two groups
v. difference in the use of supplementation to
expressed breast milk, such as formula or donor
breast milk between the two groups during the
study period (day 14 and 28)
vi. rates of breastfeeding, use of supplementation, such
as formula or donor breast milk at 40 weeks post
conceptual age (term) and at 6 weeks post term
between the different groups
vii. potential differences in adverse events, in particular,
those related to gastrointestinal or cardiac
difficulties
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All analyses will be carried out using SAS Version 9.1
(SAS Institute, Cary, NC, USA). Descriptive statistics
will be calculated for all variables of interest. Continuous
measures will be summarized using means and standard
deviations whereas categorical measures will be sum-
marized using counts and percentages.
The primary outcome will be assessed between groups
using a logistic regression model. This model will ac-
count for correlation among observations taken at the
same centre as well as multiple births by the same
mother using generalized estimating equations. The
model will take into account variables such as gesta-
tional age and days post delivery. The number of vari-
ables included in the model will be determined using
regression modeling guidelines (i.e. for logistic models,
the maximum number of variables allowed will equal
the number of observations in the smallest of the two
outcome categories divided by 10). Prior to analysis,
variables will be assessed for the presence of multi-
collinearity (tolerance statistic < 0.4), and in this case,
only one member of a correlated set will be retained in
the model.
The secondary outcomes involving mean difference in
the tabulated volume in breast milk will be assessed
using a repeated measure analysis of covariance compar-
ing the different groups across the time points of inter-
est, adjusting for correlation among observations taken
at the same centre and on the same subject. The model
will assess differences between groups, differences over
time (within-subject differences), and the group by time
interaction adjusting for gestational age and days post
delivery.
A linear regression model will be run to assess the re-
lationship between gestational ages at time of delivery
on the volume of milk. The model will include group,
gestational age (23–26 weeks, or 27–29 weeks), as well
as the group by age interaction term. Another linear re-
gression model will be run to assess the relationship be-
tween timing of inadequate milk supply post delivery on
the volume of milk. The model will include group, tim-
ing (7–14 days, 15–21 days), as well as the group by tim-
ing interaction term. All regression models conducted in
this study will be run using likelihood based methods to
account for missing data. The models will also treat
twins or triplets as a correlated set of data to adjust for
their dependent nature.
Use of supplementation, rates of breastfeeding, and
adverse events will be assessed using a chi-square ana-
lysis comparing groups.
Discussion
Currently, there is no clear approach in managing
mothers of preterm infants experiencing an inadequateproduction of breast milk. With EMPOWER, we
hypothesize that domperidone, through its pharmaco-
logic action on increasing prolactin levels, will assist
mothers of very preterm infants, experiencing inad-
equate breast milk production, in increasing breast milk
volumes to a level identified as being sufficient for con-
tinued pumping in the hospitalization period. We also
hope to determine the safety and efficacy of domperi-
done in helping a mother who is experiencing an inad-
equate milk supply, and how it should be considered in
the care of the mother and her preterm infant without
causing adverse consequences to either the mother or
infant.
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